Oxidative Medicine and Cellular Longevity
Volume 2022 (2022), Article ID 5945828, 10 pages
https://doi.org/10.1155/2022/5945828
Pursuing Diabetic Nephropathy through Aqueous Humor Proteomics Analysis
Correspondence should be addressed to Hanyi Min
Huan Chen and Tan Wang contributed equally to this work.
Received 20 July 2022; Revised 1 September 2022; Accepted 14 September 2022; Published 29 September 2022
Academic Editor: Shao Liang
Copyright © 2022 Huan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
In order to determine the possible aqueous humor (AH) proteins involved in diabetic nephropathy (DN) progression, we performed gel electrophoresis-liquid chromatography-tandem mass spectrometry protein profiling of AH samples from 5 patients with proliferative diabetic retinopathy (PDR) combined DN and 5 patients with PDR. Function enrichment analyses were carried out after the identification of differentially expressed proteins (DEPs). Protein-protein interaction networks were then built and the Search Tool for the Retrieval of Interacting Genes database and CytoNCA plugin in Cytoscape were utilized for module analysis. Ingenuity Pathway Analysis (IPA) was used to analyze disease and biological function, Tox function enrichment and upstream regulatory molecules/networks. Fifty-four DEPs were finally confirmed, whose enriched functions and pathways covered cell adhesion, extracellular exosome, complement activation, complement and coagulation cascades, etc. Nine hub genes were identified, including NCAM1, PLG, APOH, C3, PSAP, RBP4, CDH2, NUCB1, and GNS. IPA showed that C3 and PLG are involved in renal and urological system abnormalities. Conclusively, DEPs and hub proteins confirmed in this exploratory AH proteomic analysis may help us gain a deeper understanding of the molecular mechanisms involved in DN progression, providing novel candidate biomarkers for the early detection for diagnosis of DN.
1. Introduction
Diabetes mellitus is a chronic metabolic condition that can result in life-threatening complications [1–3]. Microvascular problems, like diabetic nephropathy (DN) and retinopathy (DR), are commonly associated with hyperglycemia and metabolic dysfunction in diabetes. Among microvascular complications, DN is a prime reason for end-stage renal failure globally. Currently, the clinical diagnosis of DN is based on proteinuria and/or altered glomerular filtration rate. DN progression is featured by a gradual increase in the rate of urinary albumin excretion, developing from normoalbuminuria to microalbuminuria and to macroalbuminuria. Nonetheless, due to considerable interindividual variability, conventional tests have significant limits for detection of DN in the early stages [4, 5]. Therefore, it is valuable to develop a more sensitive means to detect DN at an early stage.
Proteomics, which is based on mass spectrometry, has particular potential for identifying novel biomarkers in biofluids and could serve as the basis for new clinical testing. By analyzing the overall protein profiles in body fluids (urine, blood, etc.), proteomics can identify invaluable disease-specific biomarkers [6, 7]. In many patients with renal diseases, disease pathophysiology-related biomarkers have been identified through urine and plasma proteomic analyses, with some of them put into practical clinical application [8–10].
Because DN often follows DR in the development of microvascular complications of diabetes, risk factors for DR include diabetes control and duration, elevated blood lipid levels, race, inflammatory cytokine levels in serum, and aqueous humor (AH) [11, 12]. Thus, it is worth to set DR combined with DN as the observation group and DN as the control group to explore the AH proteins modulated by DN. However, most studies usually perform quantitative proteomic analysis on urine and plasma specimens, and it is unclear whether differences in urine protein levels across cases in these analyses are due to differences in plasma protein levels or to elevated secreted protein levels caused by kidney injury [13]. To our knowledge, no proteomic study using AH has been performed to explore the key molecules.
This research employs the protein profiling method of gel electrophoresis plus liquid chromatography-tandem mass spectrometry (GeLC-MS/MS) and conducts bioinformatic analysis of proteins with markedly changed expression among groups and aims at identifying DN-modulated AH proteins in clinically well-defined diabetic populations while highlighting the biological processes underlying disease etiopathogenesis.
2. Materials and Method
2.1. Subjects
In this prospective case series research, 10 eyes from 10 diabetic patients (5 with PDR and 5 with PDR+DN), who were examined by the same internal medicine physician between March 2019 and October 2020 in the Peking Union Medical College Hospital, were analyzed. DN was confirmed by a 24-hour urinary albumin excretion of >300 mg, and PDR was confirmed by an ophthalmologist. Patients were clinically diagnosed with active PDR, presenting with repeated vitreous bleeding and/or retinal detachment as a result of fibrovascular membrane neovascularization. This study, after obtaining the approval from the Ethics Committee of our hospital and informed consent from all participants, was conducted strictly following the Declaration of Helsinki.
Patients all underwent pretreatment ocular examinations testing intraocular pressure (IOP), axial length, best-corrected visual acuity, and corneal endothelial cell counts, as well as ultrasound biomicroscopy of anterior and posterior segments.
Cases meeting any of the following were ruled out: (1) other retinal diseases besides DR; (2) other diseases of the eyes like glaucoma; (3) intraocular inflammation or infections; (4) intraocular surgery in the past 6 months; (5) previous penetrating ocular trauma; and (6) inability to receive eye operation because of recent myocardial infarction, uncontrolled diabetes/hypertension, cerebrovascular events, etc.
2.2. Sample Collection and Preparation
Following informed permission, patients received three days of prophylactic topical Levofloxacin instillation. Following topical anesthetic and sterilization of the operation field, patients were given an intravitreal anti-VEGF injection (Conbercept, Aflibercept, or Ranibizumab with a dosage of 0.05 mg, 2 mg, and 0.05 mg, respectively) via the superotemporal pars plana that was located 4 mm behind the limbus. Prior to anti-VEGF therapy, AH samples were taken from each patient for 10 minutes of centrifugation (13000 g, 4°C), followed by storage in tuberculin syringes and −80°C refrigeration.
Supernatants of AH samples obtained via centrifugation were placed into three KD ultrafiltration tubes. Then the protein solution was replaced with a lysis buffer that was composed of 2 M Thiourea (Sigma-Aldrich, USA) +7 M Urea (Amresco 0568-1Kg, USA) +0.1% 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate [CHAPS] + protease inhibitors.
Following ultrafiltration and centrifugation, we collected 10 μL of the sample and utilized the Bradford Protein Assay Kit (Thermo 23236, USA) for protein quantification. Proteins were then trypsin digested using the modified filter-aided sample preparation (FASP) technique [14, 15]. Briefly, lysate sample reduction was accomplished by incubating in dithiothretitol (DTT; 25 mM, Bio-Rad, USA) for 30 minutes at 60°C, and the subsequent 10 minutes of 50 mM iodoacetamide alkylation in the dark. After loading the samples onto a 10 kDa cutoff ultrafiltration membrane (Sartorius, Germany), they were incubated all night long at 37°C with trypsin (enzyme-to-protein ratio: 1 : 50). Following three 50 mM triethylammonium bicarbonate buffer (300 mL; Sigma T7408, USA) rinses, the samples were treated with 10 minutes of spinning at 12,000 g. Ziptip C18 pipette tips desalted peptides as instructed by the manufacturer’s instructions.
After activation of the C18 solid phase extraction column and equilibration with ACN and 2% ACN, 0.1% FA, the sample loaded was pipetted 10 times, and then desalted and eluted with 2% and 50% ACN, 0.1% FA, respectively. After being collected into a rotary vacuum drier, the eluent was refrigerated at −80°C until use.
To build a data-independent acquisition (DIA) Spectral Library, dried peptides were subjected to 0.1% formic acid (FA; Thermo A117-50, USA) resuspension and the subsequent collection for sample dividing into samples with equal lysate quantities. The rest specimens were used with the Biognosys iRT kit, including the preparation of a 10 × iRT buffer and the subsequent addition of it to each sample at 9 : 1.
2.3. High-pH Reversed-Phase Fractionation
The digest samples were separated by additional high-pH reversed-phase chromatography. The RIGOL L-3000 system was utilized for the separation of mixed peptides in a 30 μg digest specimen using a reverse chromatography column (RIGOL, Beijing, China). After dissolution of peptides in mobile phase A (100 μL; 2% (v/v) acetonitrile (Thermo A955-4, USA), 98% (v/v) ddH2O, pH 10), the mixture was spun down (14,000 g) for 20 minutes.
Then the mobile phase B (98% (v/v) acetonitrile, 2% (v/v) ddH2O, pH 10) was injected into the supernatants at 1 mL/min in the column in a stepwise elution mode. Mobile phase B step gradients were used to acquire individual 15 minutes eluant fractions.
2.4. Mass Spectrometric (MS) Acquisition
For MS analysis, samples of 1 μg each volume were evaluated on an EASY-nLC1000 connected to an Orbitrap Fusion™ Tribrid™ MS instrument (Thermo Scientific) with the use of an internally prepared analytical column (150 μm ×150 mm, 1.9 μm). A binary solvent system, which was prepared by 0.1% FA in H2O (A) and 0.1% FA in ACN (B), was adopted, and the linear gradient settings were as follows: 3-8% B/4 min, 8-22% B/65 min, 22-35% B/12 min, 35-90% B/4 min, and 90% B/5 min.
Using an EASY-Spray ion source, direct eluent introduction into the MS instrument was then carried out, with the spray voltage and capillary temperature set as 2.3 kV and 320°C, respectively. The whole MS scanning range was 300-1400 m/z for data-dependent acquisition- (DDA-) MS runs. With a resolution of 60,000, the MS had an under 3-stop-speed mode for 15,000 resolution MS/MS scans, while HCD had an isolation window and a normalized collision energy of 1.6 m/z and 32%, respectively. For DIA analyses, MS1 scans (automatic gain control (AGC) target 4e5 or 50 ms injection time) were performed from 300 to 1300 m/z, with DIA segmentation resolution of 30,000 (AGC target 5e5; for injection time). The collision energy was 32%, and the spectra were collected in profile mode.
2.5. Identification and Quantification of Proteins
DIA data analyses adopted Biognosys’ Spectronaut pulsar programme [16]. The default software settings were employed for targeted data analyses, where dynamic iRT was utilized for retention time prediction types with window-based correction factors. Besides, local mass calibration, as well as limitless scrambled decoy generation, was utilized. We also employ an MS2-level interference connection for fragment elimination based on interference signals while retaining ≥3 for measurement. The false discovery rate (FDR) at peptide level was 1%.
Based on the principle of parsimony, the ID picker algorithm comes with the software package was used for proteomic inference. RAW images were converted to the Spectronaut file format when conducting spectral library-based studies and were calibrated according to the global spectral library’s retention time dimension. After then, the files were used for spectrum analysis without any further retention time-based recalibration. To evaluate DDA data, Proteome Discoverer 2.3 with default settings (Trypsin/P (Promega, V5111, USA), two missed cleavages) was used. Cysteine carbamidomethylation and methionine and acetyl (protein N terminal) oxidation were used as the fixed modification and the variable modifications in the search criteria, respectively. The initial mass tolerances for precursor and fragment ions were set at 10 ppm and 0.02 Da, respectively [17]. UniProt human (uniprot_human_73940_20190731_iRT.fasta) and Biognosys’ iRT peptides fasta (uploaded to the public repository) databases acted as references for DDA data retrieval.
2.6. Proteomic Analyses
After minimizing biases between experiments through median normalization, protein expression differences were then evaluated via a Student’s -test. Statistically significant differentially expressed proteins (DEPs) were defined using and fold-change cut-offs of >1.5 and <0.667 (metabolite ratios >1.5 and <0.667 were classified as increased and decreased, respectively). Data normalization, DEPs, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed in ‘Wu Kong’ platform (URL: https://www.omicsolution.com/wkomics/main/) [18]. Protein-protein interaction (PPI) networks of DEPs were constructed using the Search Tool for the Retrieval of Interacting Genes (STRING), with a combined score above 0.4 indicating statistical significance. Betweenness centrality was measured using CytoNCA plugin in Cytoscape v3.9.1 for the hub gene screening [19, 20]. “Without weight” was set as the parameter. IPA (Ingenuity Systems, USA) was utilized to discuss disease and biological function, Tox function enrichment and upstream regulatory molecules/networks.
2.7. Statistical Processing
A normality test was performed on all data. Continuous variables of normal distribution are expressed as , and categorical variables are given numbers (percentages). Independent Student’s -test, Fisher’s exact test or the Chi-squared test explored the intergroup difference of characteristics. A value <0.05 was the significance level. R Statistical Software (RStudio, Inc., Boston, MA, USA; version 1.0.153) performed statistical analyses and plotting.
3. Results
3.1. Identification of DEPs
Figure 1 shows the workflow of our study. Table 1 shows patients’ clinical features: PDR (DM_R) and PDR and nephropathy (DM_R+N) patients, 5 cases each with corresponding average ages and years (; Table 1). The two groups were statistically similar regarding gender ratio, age, HbA1c, duration of diabetes, fasting blood glucose (FBG), and indication for surgery. Macroalbuminuria was present in the DM_R+N group (>300 mg/24 h).